سوق المكونات الصيدلانية النشطة (API) في منطقة آسيا والمحيط الهادئ – اتجاهات الصناعة والتوقعات حتى عام 2028

Customize Your Report تخصيص تقريرك Buy Now اشتري الآن Free Sample Report تقرير عينة مجاني
Home Pharmaceutical Asia Pacific Active Pharmaceutical Ingredient Api Market
Request for TOC طلب جدول المحتويات Speak to Analyst تحدث إلى المحلل Buy Now اشتري الآن Inquire Before Buying استفسر قبل Free Sample Report تقرير عينة مجاني

سوق المكونات الصيدلانية النشطة (API) في منطقة آسيا والمحيط الهادئ – اتجاهات الصناعة والتوقعات حتى عام 2028

  • Pharmaceutical
  • Published Report
  • Apr 2021
  • Asia-Pacific
  • 350 الصفحات
  • عدد الجداول: 419
  • عدد الأرقام: 38
Buy Now اشتري الآن

>سوق المكونات الصيدلانية النشطة (API) في منطقة آسيا والمحيط الهادئ، حسب الجزيء (الجزيء الصغير، الجزيء الكبير)، النوع ( المكونات الصيدلانية النشطة المبتكرة ، المكونات الصيدلانية النشطة المبتكرة العامة)، نوع الشركة المصنعة (شركة تصنيع API الأسير، شركة تصنيع API التجارية)، التوليف (المكونات الصيدلانية النشطة الاصطناعية والمكونات الصيدلانية النشطة للتكنولوجيا الحيوية)، التوليف الكيميائي (أسيتامينوفين، أرتيميسينين، ساكساجليبتين، كلوريد الصوديوم، إيبوبروفين، لوزارتان البوتاسيوم، إينوكسابارين الصوديوم، روفيناميد، نابروكسين، تاموكسيفين، أخرى)، نوع الدواء ( الأدوية الموصوفة ، الأدوية المتاحة دون وصفة طبية)، الاستخدام (السريري، البحثي)، الفعالية (المكونات الصيدلانية النشطة ذات الفعالية المنخفضة إلى المتوسطة، المكونات الصيدلانية النشطة ذات الفعالية القوية إلى القوية للغاية)، التطبيق العلاجي (أمراض القلب والجهاز العصبي المركزي والأعصاب والأورام والعظام والغدد الصماء وأمراض الرئة وأمراض الجهاز الهضمي وأمراض الكلى وطب العيون وتطبيقات علاجية أخرى)، الدولة (اليابان والصين وأستراليا والهند وكوريا الجنوبية وسنغافورة وإندونيسيا وتايلاند وماليزيا والفلبين وفيتنام وبقية دول آسيا والمحيط الهادئ) اتجاهات الصناعة والتوقعات حتى عام 2028

سوق المكونات الصيدلانية النشطة (API) في منطقة آسيا والمحيط الهادئ

تحليل السوق والرؤى : سوق المكونات الصيدلانية النشطة (API) في منطقة آسيا والمحيط الهادئ

من المتوقع أن يكتسب سوق المكونات الصيدلانية النشطة (API) نموًا في السوق في الفترة المتوقعة من 2021 إلى 2028. تحلل Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب بنسبة 7.5٪ في الفترة المتوقعة من 2021 إلى 2028 ومن المتوقع أن يصل إلى 86222.48 مليون دولار أمريكي بحلول عام 2028. إن الانتشار المتزايد لمختلف الاضطرابات المزمنة وزيادة عدد السكان المسنين هي المحركات الرئيسية التي دفعت الطلب على سوق المكونات الصيدلانية النشطة (API) في الفترة المتوقعة.

  • في اللغة اليونانية، تُسمى الكلمة التقليدية للمكونات الصيدلانية النشطة (API) pharmacon أو pharmakon والتي ترمز إلى مادة سحرية أو عقار. المكونات الصيدلانية النشطة كما هو موضح في ICH Q7 هي "أي مادة أو مجموعة من المواد المقصود استخدامها في تصنيع منتج دوائي والتي تصبح عند استخدامها في إنتاج الدواء مكونًا صيدلانيًا نشطًا. تُستخدم هذه المواد لتوفير النشاط الدوائي.

إن الزيادة في التقدم التكنولوجي من شأنها أن تعزز القدرات وتعزز مهارات التصنيع لدى اللاعبين في السوق، حيث يتعين على الشركات المصنعة توفير المواد الصيدلانية الفعالة بكميات كبيرة وتلبية طلب المستهلكين، وهو ما يمكن أن يدفع نمو سوق المكونات الصيدلانية الفعالة. إن توافر الأدوية دون المستوى والمقلدة يعمل كقيد لإعاقة الطلب على سوق المكونات الصيدلانية الفعالة. إن زيادة الاستثمار في الأبحاث المتعلقة بتطوير المواد الصيدلانية الفعالة من شأنها أن تزيد من فرص النمو لسوق المكونات الصيدلانية الفعالة. إن الانقطاع في سلسلة توريد المواد الصيدلانية الفعالة أثناء انتشار فيروس كورونا المستجد يشكل تحديًا لمقدمي الرعاية الصحية، وهو ما قد يشكل تحديًا لسوق المكونات الصيدلانية الفعالة.

يقدم تقرير سوق المكونات الصيدلانية النشطة (API) تفاصيل عن حصة السوق والتطورات الجديدة وتحليل خط أنابيب المنتجات وتأثير اللاعبين المحليين والمحليين في السوق وتحليل الفرص من حيث جيوب الإيرادات الناشئة والتغييرات في لوائح السوق وموافقات المنتجات والقرارات الاستراتيجية وإطلاق المنتجات والتوسعات الجغرافية والابتكارات التكنولوجية في السوق. لفهم التحليل وسيناريو السوق، اتصل بنا للحصول على موجز محلل، وسيساعدك فريقنا في إنشاء حل لتأثير الإيرادات لتحقيق هدفك المنشود.

سوق المكونات الصيدلانية النشطة (API) في منطقة آسيا والمحيط الهادئ

نطاق سوق المكونات الصيدلانية النشطة (API) وحجم السوق في منطقة آسيا والمحيط الهادئ

يتم تقسيم سوق المكونات الصيدلانية النشطة (API) على أساس الجزيء والنوع ونوع الشركة المصنعة والتوليف والتوليف الكيميائي ونوع الدواء والاستخدام والفعالية والتطبيق العلاجي. يساعدك النمو بين القطاعات على تحليل جيوب النمو والاستراتيجيات المتخصصة للتعامل مع السوق وتحديد مجالات التطبيق الأساسية والاختلاف في الأسواق المستهدفة.

  • على أساس الجزيء، يتم تقسيم سوق المكونات الصيدلانية النشطة (API) إلى جزيء صغير وجزيء كبير. في عام 2021، من المتوقع أن تهيمن شريحة الجزيئات الصغيرة على سوق المكونات الصيدلانية النشطة (API) بسبب العدد المتزايد من الموافقات التنظيمية وارتفاع البحث والتطوير على الجزيئات الصغيرة الجديدة بسبب قدرتها العالية على الاختراق.
  • على أساس النوع، يتم تقسيم سوق المكونات الصيدلانية النشطة (API) إلى مكونات صيدلانية نشطة مبتكرة ومكونات صيدلانية نشطة عامة. في عام 2021، من المتوقع أن تهيمن شريحة المكونات الصيدلانية النشطة المبتكرة على سوق المكونات الصيدلانية النشطة (API) بسبب التكلفة العالية للمكونات الصيدلانية النشطة المبتكرة مقارنة بالمكونات الصيدلانية النشطة العامة وارتفاع موافقة إدارة الغذاء والدواء على الكيانات الجزيئية الجديدة.
  • على أساس نوع الشركة المصنعة، يتم تقسيم سوق المكونات الصيدلانية النشطة (API) إلى شركة تصنيع API أسيرة وشركة تصنيع API تجارية. في عام 2021، من المتوقع أن تهيمن شريحة شركة تصنيع API الأسيرة على سوق المكونات الصيدلانية النشطة (API) بسبب الاستثمار الضخم من قبل كبار اللاعبين في السوق لتوليد مرافق تصنيع عالية الجودة وسهولة توافر المواد الخام.
  • على أساس التركيب، يتم تقسيم سوق المكونات الصيدلانية النشطة (API) إلى مكونات صيدلانية نشطة اصطناعية ومكونات صيدلانية نشطة بيولوجية. في عام 2021، من المتوقع أن تهيمن شريحة المكونات الصيدلانية النشطة الاصطناعية على سوق المكونات الصيدلانية النشطة (API) بسبب البروتوكول السهل لتركيب الجزيئات والمبادئ التوجيهية التنظيمية الأقل صرامة وفي السنوات القادمة، ستنتهي براءات الاختراع للعديد من الجزيئات الاصطناعية.
  • على أساس التركيب الكيميائي، يتم تقسيم سوق المكونات الصيدلانية النشطة (API) إلى أسيتامينوفين ، أرتيميسينين، ساكساجليبتين، كلوريد الصوديوم ، إيبوبروفين لوسارتان البوتاسيوم، إينوكسابارين الصوديوم، روفيناميد، نابروكسين، تاموكسيفين وغيرها. في عام 2021، من المتوقع أن تهيمن شريحة ساكساجليبتين على سوق المكونات الصيدلانية النشطة (API) بسبب التكلفة العالية للمكونات الصيدلانية النشطة وارتفاع حالات الإصابة بمرض السكري في جميع أنحاء العالم.
  • على أساس نوع الدواء، يتم تقسيم سوق المكونات الصيدلانية النشطة (API) إلى أدوية بوصفة طبية وأدوية بدون وصفة طبية. في عام 2021، تهيمن شريحة الأدوية الموصوفة طبيًا على سوق المكونات الصيدلانية النشطة (API) بسبب التكلفة العالية للأدوية مما سيؤدي إلى زيادة المكونات الصيدلانية النشطة وتكلفة تصنيع المكونات الصيدلانية النشطة.
  • على أساس الاستخدام، يتم تقسيم سوق المكونات الصيدلانية النشطة (API) إلى سريرية وبحثية . في عام 2021، من المتوقع أن يهيمن القطاع السريري على سوق المكونات الصيدلانية النشطة (API) بسبب العدد المتزايد من الأمراض التي تتطلب إمدادًا مستمرًا من المكونات الصيدلانية النشطة والمواد الخام.
  • على أساس الفعالية، يتم تقسيم سوق المكونات الصيدلانية النشطة (API) إلى مكونات صيدلانية نشطة منخفضة إلى متوسطة الفعالية ومكونات صيدلانية نشطة قوية إلى قوية للغاية. في عام 2021، من المتوقع أن تهيمن شريحة المكونات الصيدلانية النشطة منخفضة إلى متوسطة الفعالية على سوق المكونات الصيدلانية النشطة (API) بسبب سميتها الأقل وطبيعتها الأقل خطورة.
  • على أساس التطبيق العلاجي، يتم تقسيم سوق المكونات الصيدلانية النشطة (API) إلى أمراض القلب والجهاز العصبي المركزي والأعصاب والأورام والعظام والغدد الصماء وأمراض الرئة وأمراض الجهاز الهضمي وأمراض الكلى وطب العيون وتطبيقات علاجية أخرى. في عام 2021، من المتوقع أن يهيمن قطاع أمراض القلب على سوق المكونات الصيدلانية النشطة (API) بسبب العدد المتزايد من أمراض القلب مثل النوبات القلبية والانسداد الرئوي وغيرها.

تحليل سوق المكونات الصيدلانية النشطة (API) على مستوى الدولة

يتم تحليل سوق المكونات الصيدلانية النشطة (API) ويتم توفير معلومات حجم السوق على أساس البلد والجزيء والنوع ونوع الشركة المصنعة والتوليف والتوليف الكيميائي ونوع الدواء والاستخدام والفعالية والتطبيق العلاجي كما هو مذكور أعلاه.

الدول التي يغطيها تقرير سوق المكونات الصيدلانية النشطة (API) في منطقة آسيا والمحيط الهادئ هي اليابان والصين وأستراليا والهند وكوريا الجنوبية وسنغافورة وإندونيسيا وتايلاند وماليزيا والفلبين وفيتنام وبقية دول آسيا والمحيط الهادئ.

تسيطر الصين على سوق المكونات الدوائية الفعالة (API) في منطقة آسيا والمحيط الهادئ بفضل المبادرات الحكومية لإنتاج المكونات الدوائية الفعالة.   

كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغييرات في التنظيم في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة والقوانين التنظيمية ورسوم الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية في منطقة آسيا والمحيط الهادئ والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل توقعات لبيانات الدولة.

إن زيادة انتشار الاضطرابات المزمنة المختلفة يعزز نمو سوق المكونات الصيدلانية النشطة (API)

يوفر لك سوق المكونات الصيدلانية النشطة (API) أيضًا تحليلًا تفصيليًا للسوق لكل بلد ينمو في صناعة المكونات الصيدلانية النشطة (API) مع مبيعات أدوية المكونات الصيدلانية النشطة (API) وتأثير التقدم في تكنولوجيا المكونات الصيدلانية النشطة (API) والتغييرات في السيناريوهات التنظيمية مع دعمها لسوق المكونات الصيدلانية النشطة (API). البيانات متاحة للفترة التاريخية من 2010 إلى 2019.

تحليل المنافسة وحصة سوق المكونات الصيدلانية النشطة (API)

يوفر المشهد التنافسي لسوق المكونات الصيدلانية النشطة (API) تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والمالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وخطوط أنابيب تجارب المنتجات، وموافقات المنتج، وبراءات الاختراع، وعرض المنتج والتنفس، وهيمنة التطبيق، ومنحنى شريان الحياة التكنولوجي. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركة فيما يتعلق بسوق المكونات الصيدلانية النشطة (API).

الشركات الكبرى التي تتعامل في المكونات الصيدلانية النشطة (API) هي Dr. Reddy's Laboratories Ltd. وSun Pharmaceutical Industries Ltd. وPfizer Inc. وSanofi وGlaxoSmithKline plc. وAarti Industries Limited وRecipharm AB وJubilant Pharmova Limited وLUPIN وAurobindo Pharma وAbbVie Inc. وAstraZeneca وAlkem Labs وAlbemarle Corporation وSaneca Pharmaceuticals وUnichem Laboratories وNeuland Laboratories Ltd. وDivi's Laboratories Limited. وHIKAL Ltd. وViatris Inc. وMerck KGaA وNovo Nordisk A/S وSandoz International GmbH وTeva Pharmaceutical Industries Ltd. وBASF SE وPiramal Pharma Solutions وغيرها. يفهم محللو DBMR نقاط القوة التنافسية ويوفرون تحليلًا تنافسيًا لكل منافس على حدة. 

كما تقوم الشركات العالمية أيضًا بمبادرة إطلاق العديد من المنتجات والاتفاقيات، مما يساهم أيضًا في تسريع سوق المكونات الصيدلانية النشطة (API).

على سبيل المثال،

  • في ديسمبر 2019، تعاونت شركة AbbVie Inc. مع Scripps Research من أجل تعزيز البحث لاكتشاف أدوية جديدة تستهدف مجموعة من الأمراض، بما في ذلك مجالات علم الأورام وعلم المناعة وغيرها. وفقًا لاتفاقية التعاون، ستجري Scripps Research أنشطة البحث قبل السريرية لتطوير علاجات جديدة. ساعد هذا التعاون الشركة على تطوير أدويتها الجديدة للمرضى مما أدى في النهاية إلى زيادة إيرادات الشركة.

يعمل التعاون وإطلاق المنتج وتوسيع الأعمال والجوائز والتقدير والمشاريع المشتركة والاستراتيجيات الأخرى من قبل اللاعبين في السوق على تعزيز سوق الشركة في سوق المكونات الصيدلانية النشطة (API) مما يوفر أيضًا فائدة للمنظمة لتحسين عروضها للمكونات الصيدلانية النشطة (API).

SKU-

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

Sample Image انقر على الصورة للتكبير
  • لوحة معلومات تحليل البيانات التفاعلية
  • لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
  • إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
  • تحليل المنافسين باستخدام لوحة معلومات تفاعلية
  • آخر الأخبار والتحديثات وتحليل الاتجاهات
  • استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 MOLECULE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET TYPE OF MANUFACTURER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COUNTRIES WITH DATA OF IMPORTS AND EXPORTS

4.2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COLOMBIA DATA OF THE ORIGIN COUNTRY OF THE IMPORTS

4.3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COLOMBIA DATA OF THE IMPORTS AND EXPORTS BY MOLECULES IN VALUES AND VOLUMES

5 PIPELINE ANALYSIS

6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: REGULATORY FRAMEWORK

6.1 CURRENT GOODS MANUFACTURING PRACTICES

6.2 REGULATORY REQUIREMENTS FOR REGISTRATION OF API IN THE U.S. AND EU

6.3 REGISTRATION OF API IN THE U.S.

6.4 REGISTRATION OF API IN EUROPE

6.5 REGULATORY REQUIREMENTS IN INDIA

6.6 REGULATORY FRAMEWORK IN CHINA

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF VARIOUS CHRONIC DISORDERS

7.1.2 INCREASE IN AGING POPULATION

7.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING

7.1.4 INCREASING DISEASE AWARENESS AND EDUCATION

7.1.5 PATENT EXPIRY OF BRANDED ACTIVE PHARMACEUTICAL INGREDIENTS (API)

7.2 RESTRAINTS

7.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS

7.2.2 HIGH MANUFACTURING COST

7.2.3 ADVERSE HEALTH EFFECTS OF EXPOSURE TO ACTIVE PHARMACEUTICAL INGREDIENTS (API)

7.3 OPPORTUNITIES

7.3.1 COLLABORATION AND ACQUISITION AMONG THE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS

7.3.2 INCREASING HEALTHCARE EXPENDITURE

7.3.3 RISING INVESTMENT IN RESEARCH REGARDING THE DEVELOPMENT OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)

7.3.4 SOARING NUMBER OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS

7.4 CHALLENGES

7.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19

7.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES

7.4.3 PRODUCT RECALLS

8 IMPACT OF COVID 19 PANDEMIC ON THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON SUPPLY CHAIN

8.3 IMPACT ON DEMAND

8.4 STRATEGIC DECISIONS FOR MANUFACTURERS

8.5 CONCLUSION

9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE

9.1 OVERVIEW

9.2 SMALL MOLECULE

9.3 LARGE MOLECULE

10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE

10.1 OVERVIEW

10.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

10.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER

11.1 OVERVIEW

11.2 CAPTIVE API MANUFACTURERS

11.3 MERCHANT API MANUFACTURERS

11.3.1 TYPE

11.3.1.1 Merchant Innovative API Manufacturers

11.3.1.2 Merchant Generic API Manufacturers

11.3.2 TYPE OF SYNTHESIS

11.3.2.1 Merchant Synthetic API Manufacturers

11.3.2.2 Merchant Biotech API Manufacturers

12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS

12.1 OVERVIEW

12.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT

12.2.1 INNOVATIVE SYNTHETIC APIS

12.2.2 GENERIC SYNTHETIC APIS

12.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT

12.3.1 TYPE

12.3.1.1 Innovative Biotech APIs

12.3.1.2 Generic Biotech APIs

12.3.2 PRODUCT

12.3.2.1 Monoclonal Antibodies

12.3.2.2 Adalimumab

12.3.2.3 Ustekinumab

12.3.2.4 Secukinumab

12.3.2.5 Cetuximab

12.3.2.6 Daclizumab

12.3.2.7 Omalizumab

12.3.2.8 Vedolizumab

12.3.2.9 Abciximab

12.3.2.10 Efalizumab

12.3.2.11 Others

12.3.2.2 Cytokines

12.3.2.2.1 Interleukin-2

12.3.2.2.2 Interferon Beta-1A

12.3.2.2.3 Interleukin-10

12.3.2.2.4 Interleukin-9

12.3.2.2.5 Erythropoietin

12.3.2.2.6 Others

12.3.2.3 Hormones & Growth Factors

12.3.2.4 Blood Factors

12.3.2.5 Recombinant Vaccines

12.3.2.6 Therapeutic Enzymes

12.3.3 EXPRESSION SYSTEM

12.3.3.1 Mammalian Expression System

12.3.3.2 Yeast Expression System

12.3.3.3 Microbial Expression System

12.3.3.4 Insect Expression System

12.3.3.5 Others Expression System

13 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS

13.1 OVERVIEW

13.2 SAXAGLIPTIN

13.3 ENOXAPARIN SODIUM

13.4 RUFINAMIDE

13.5 TAMOXIFEN

13.6 ARTEMISININ

13.7 LOSARTAN POTASSIUM

13.8 NAPROXEN

13.9 IBUPROFEN

13.1 ACETAMINOPHEN

13.11 SODIUM CHLORIDE

13.12 OTHERS

14 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG

14.1 OVERVIEW

14.2 PRESCRIPTION DRUGS

14.3 OVER-THE-COUNTER

15 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE

15.1 OVERVIEW

15.2 CLINICAL

15.3 RESEARCH

16 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY

16.1 OVERVIEW

16.2 LOW-TO-MODERATE POTENT ACTIVE PHARMACEUTICAL INGREDIENT

16.3 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT

17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION

17.1 OVERVIEW

17.2 CARDIOLOGY

17.2.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.2.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.3 CNS & NEUROLOGY

17.3.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.3.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.4 ONCOLOGY

17.4.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.4.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.5 GASTROENTEROLOGY

17.5.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.5.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.6 PULMONOLOGY

17.6.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.6.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.7 ENDOCRINOLOGY

17.7.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.7.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.8 NEPHROLOGY

17.8.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.8.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.9 ORTHOPEDIC

17.9.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.9.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.1 OPHTHALMOLOGY

17.10.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.10.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

17.11 OTHERS

17.11.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT

17.11.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT

18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY REGION

18.1 ASIA-PACIFIC

18.1.1 CHINA

18.1.2 INDIA

18.1.3 JAPAN

18.1.4 AUSTRALIA

18.1.5 SOUTH KOREA

18.1.6 SINGAPORE

18.1.7 MALAYSIA

18.1.8 THAILAND

18.1.9 INDONESIA

18.1.10 PHILIPPINES

18.1.11 VIETNAM

18.1.12 REST OF ASIA-PACIFIC

19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

20 SWOT ANALYSIS

21 COMPANY PROFILE

21.1 TEVA PHARMECEUTICALS INDUSTRIES LTD.

21.1.1 COMPANY SNAPSHOT

21.1.2 RECENT FINANCIALS

21.1.3 COMPANY SHARE ANALYSIS

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENT

21.2 PFIZER, INC.

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 COMPANY SHARE ANALYSIS

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 SANOFI

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 COMPANY SHARE ANALYSIS

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENTS

21.4 MERCK KGAA

21.4.1 COMPANY SNAPSHOT

21.4.2 REVENUE ANALYSIS

21.4.3 COMPANY SHARE ANALYSIS

21.4.4 PRODUCT PORTFOLIO

21.4.5 RECENT DEVELOPMENT

21.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)

21.5.1 COMPANY SNAPSHOT

21.5.2 REVENUE ANALYSIS

21.5.3 PRODUCT PORTFOLIO

21.5.4 RECENT DEVELOPMENT

21.6 AUROBINDO PHARMA

21.6.1 COMPANY SNAPSHOT

21.6.2 REVENUE ANALYSIS

21.6.3 PRODUCT PORTFOLIO

21.6.4 RECENT DEVELOPMENT

21.7 ALBEMARLE CORPORATION

21.7.1 COMPANY SNAPSHOT

21.7.2 REVENUE ANALYSIS

21.7.3 PRODUCT PORTFOLIO

21.7.4 RECENT DEVELOPMENTS

21.8 ASTRAZENECA

21.8.1 COMPANY SNAPSHOT

21.8.2 REVENUE ANALYSIS

21.8.3 PRODUCT PORTFOLIO

21.8.4 RECENT DEVELOPMENT

21.9 DIVI’S LABORATORIES LIMITED

21.9.1 COMPANY SNAPSHOT

21.9.2 REVENUE ANALYSIS

21.9.3 PRODUCT PORTFOLIO

21.9.4 RECENT DEVELOPMENTS

21.1 DR. REDDY’S LABORATORY LTD.

21.10.1 COMPANY SNAPSHOT

21.10.2 RECENT FINANCIALS

21.10.3 PRODUCT PORTFOLIO

21.10.4 RECENT DEVELOPMENT

21.11 PIRAMAL PHARMA SOLUTIONS

21.11.1 COMPANY SNAPSHOT

21.11.2 PRODUCT PORTFOLIO

21.11.3 RECENT DEVELOPMENTS

21.12 AARTI INDUSTRIES LIMITED

21.12.1 COMPANY SNAPSHOT

21.12.2 REVENUE ANALYSIS

21.12.3 PRODUCT PORTFOLIO

21.12.4 RECENT DEVELOPMENT

21.13 ABBVIE INC

21.13.1 COMPANY SNAPSHOT

21.13.2 REVENUE ANALYSIS

21.13.3 PRODUCT PORTFOLIO

21.13.4 RECENT DEVELOPMENTS

21.14 ALKEM LABS

21.14.1 COMPANY SNAPSHOT

21.14.2 REVENUE ANALYSIS

21.14.3 PRODUCT PORTFOLIO

21.14.4 RECENT DEVELOPMENTS

21.15 ALEMBIC PHARMACEUTICALS LIMITED

21.15.1 COMPANY SNAPSHOT

21.15.2 REVENUE ANALYSIS

21.15.3 PRODUCT PORTFOLIO

21.15.4 RECENT DEVELOPMENTS

21.16 BASF SE

21.16.1 COMPANY SNAPSHOT

21.16.2 RECENT FINANCIALS

21.16.3 PRODUCT PORTFOLIO

21.16.4 RECENT DEVELOPMENT

21.17 CIPLA INC.

21.17.1 COMPANY SNAPSHOT

21.17.2 RECENT FINANCIALS

21.17.3 PRODUCT PORTFOLIO

21.17.4 RECENT DEVELOPMENTS

21.18 CORDENPHARMA INTERNATIONAL

21.18.1 COMPANY SNAPSHOT

21.18.2 PRODUCT PORTFOLIO

21.18.3 RECENT DEVELOPMENTS

21.19 GLAXOSMITHKLINE PLC

21.19.1 COMPANY SNAPSHOT

21.19.2 REVENUE FINANCIALS

21.19.3 PRODUCT PORTFOLIO

21.19.4 RECENT DEVELOPMENT

21.2 HIKAL LTD.

21.20.1 COMPANY SNAPSHOT

21.20.2 REVENUE ANALYSIS

21.20.3 PRODUCT PORTFOLIO

21.20.4 RECENT DEVELOPMENTS

21.21 JUBILANT LIFE SCIENCES LIMITED

21.21.1 COMPANY SNAPSHOT

21.21.2 REVENUE ANALYSIS

21.21.3 PRODUCT PORTFOLIO

21.21.4 RECENT DEVELOPMENT

21.22 LUPIN

21.22.1 COMPANY SNAPSHOT

21.22.2 REVENUE ANALYSIS

21.22.3 PRODUCT PORTFOLIO

21.22.4 RECENT DEVELOPMENTS

21.23 MINAKIM

21.23.1 COMPANY SNAPSHOT

21.23.2 PRODUCT PORTFOLIO

21.23.3 RECENT DEVELOPMENTS

21.24 NEULAND LABORATORIES LTD.

21.24.1 COMPANY SNAPSHOT

21.24.2 REVENUE ANALYSIS

21.24.3 PRODUCT PORTFOLIO

21.24.4 RECENT DEVELOPMENTS

21.25 NOVO NORDISK A/S

21.25.1 COMPANY SNAPSHOT

21.25.2 REVENUE ANALYSIS

21.25.3 PRODUCT PORTFOLIO

21.25.4 RECENT DEVELOPMENT

21.26 RECIPHARM AB

21.26.1 COMPANY SNAPSHOT

21.26.2 REVENUE ANALYSIS

21.26.3 PRODUCT PORTFOLIO

21.26.4 RECENT DEVELOPMENTS

21.27 SANECA PHARMACEUTICALS

21.27.1 COMPANY SNAPSHOT

21.27.2 PRODUCT PORTFOLIO

21.27.3 RECENT DEVELOPMENTS

21.28 SUN PHARMACEUTICAL INDUSTRIES LTD.

21.28.1 COMPANY SNAPSHOT

21.28.2 REVENUE ANALYSIS

21.28.3 PRODUCT PORTFOLIO

21.28.4 RECENT DEVELOPMENTS

21.29 UNICHEM LABORATORIES

21.29.1 COMPANY SNAPSHOT

21.29.2 REVENUE ANALYSIS

21.29.3 PRODUCT PORTFOLIO

21.29.4 RECENT DEVELOPMENTS

21.3 VIATRIS INC.

21.30.1 COMPANY SNAPSHOT

21.30.2 PRODUCT PORTFOLIO

21.30.3 RECENT DEVELOPMENTS

22 QUESTIONNAIRE

23 RELATED REPORTS

List of Table

TABLE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, PIPELINE ANALYSIS

TABLE 2 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE REGISTRATION PROCESS

TABLE 3 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE ADMINISTRATIVE REQUIREMENTS

TABLE 4 AGE DISTRIBUTION OF THE U.K. POPULATION (FROM 1976 TO 2046)

TABLE 5 WORLD –WIDE IMPACT OF COVID-19 ON THE PHARMACEUTICAL SECTOR

TABLE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC SMALL MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC LARGE MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC GENERIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC CAPTIVE API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC MERCHANT API MANUFACTURER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET , BY REGION, 2017-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC CYTOKINESPRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (UNITS)

TABLE 28 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (ASP)

TABLE 29 ASIA-PACIFIC SAXAGLIPTIN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, REGION, 2017-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC ENOXAPARIN SODIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC RUFINAMIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC TAMOXIFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC ARTEMISININ IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC LOSARTAN POTASSIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC NAPROXEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC IBUPROFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC ACETAMINOPHEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC SODIUM CHLORIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2019-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC PRESCRIPTION DRUGS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 43 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC CLINICAL IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 45 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 46 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 47 ASIA-PACIFIC LOW-TO-MODERATE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC POTENT-TO-HIGHLY POTENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 55 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 56 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 58 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 62 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 63 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 64 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 65 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 66 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 67 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 68 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 69 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 70 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 71 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 72 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 73 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 74 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 75 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 76 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 77 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 78 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 79 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 80 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 81 ASIA-PACIFIC CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 82 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 83 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 84 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 85 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 86 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 87 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 88 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 89 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 90 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 91 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 92 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 93 ASIA-PACIFIC GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 94 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 95 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 96 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 97 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 98 ASIA-PACIFIC OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 99 ASIA-PACIFIC OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 100 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 101 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 102 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 103 CHINA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 104 CHINA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 105 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 106 CHINA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 107 CHINA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 108 CHINA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 109 CHINA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 110 CHINA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 111 CHINA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 112 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 113 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 114 UDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 115 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 116 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 117 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 118 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 119 CHINA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 120 CHINA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 121 CHINA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 122 CHINA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 123 CHINA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 124 CHINA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 125 CHINA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 126 CHINA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 127 CHINA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 128 CHINA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 129 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 130 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 131 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 132 INDIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 133 INDIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 134 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 135 INDIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 136 INDIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 137 INDIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 138 INDIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 139 INDIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 140 INDIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 141 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 142 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 143 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 144 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 145 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 146 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 147 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 148 INDIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 149 INDIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 150 INDIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 151 INDIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 152 INDIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 153 INDIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 154 INDIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 155 INDIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 156 INDIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 157 INDIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 158 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 159 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 160 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 161 JAPAN TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 162 JAPAN TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 163 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 164 JAPAN SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 165 JAPAN TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 166 JAPAN PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 167 JAPAN MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 168 JAPAN CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 169 JAPAN EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 170 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 171 AE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 172 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 173 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 174 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 175 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 176 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 177 JAPAN CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 178 JAPAN CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 179 JAPAN ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 180 JAPAN GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 181 JAPAN PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 182 JAPAN ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 183 JAPAN NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 184 JAPAN ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 185 JAPAN OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 186 JAPAN OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 187 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 188 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 189 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 190 AUSTRALIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 191 AUSTRALIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 192 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 193 AUSTRALIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 194 AUSTRALIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 195 AUSTRALIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 196 AUSTRALIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 197 AUSTRALIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 198 AUSTRALIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 199 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 200 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 201 ISREAL ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 202 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 203 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 204 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 205 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 206 AUSTRALIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 207 AUSTRALIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 208 AUSTRALIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 209 AUSTRALIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 210 AUSTRALIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 211 AUSTRALIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 212 AUSTRALIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 213 AUSTRALIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 214 AUSTRALIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 215 AUSTRALIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 216 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 217 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 218 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 219 SOUTH KOREA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 220 SOUTH KOREA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 221 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 222 SOUTH KOREA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 223 SOUTH KOREA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 224 SOUTH KOREA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 225 SOUTH KOREA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 226 SOUTH KOREA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 227 SOUTH KOREA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 228 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 229 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 230 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 231 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 232 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 233 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 234 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 235 SOUTH KOREA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 236 SOUTH KOREA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 237 SOUTH KOREA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 238 SOUTH KOREA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 239 SOUTH KOREA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 240 SOUTH KOREA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 241 SOUTH KOREA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 242 SOUTH KOREA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 243 SOUTH KOREA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 244 SOUTH KOREA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 245 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 246 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 247 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 248 SINGAPORE TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 249 SINGAPORE TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 250 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 251 SINGAPORE SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 252 SINGAPORE TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 253 SINGAPORE PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 254 SINGAPORE MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 255 SINGAPORE CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 256 SINGAPORE EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 257 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 258 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 259 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 260 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 261 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 262 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 263 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 264 SINGAPORE CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 265 SINGAPORE CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 266 SINGAPORE ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 267 SINGAPORE GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 268 SINGAPORE PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 269 SINGAPORE ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 270 SINGAPORE NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 271 SINGAPORE ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 272 SINGAPORE OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 273 SINGAPORE OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 274 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 275 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 276 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 277 MALAYSIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 278 MALAYSIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 279 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 280 MALAYSIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 281 MALAYSIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 282 MALAYSIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 283 MALAYSIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 284 MALAYSIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 285 MALAYSIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 286 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 287 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 288 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 289 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 290 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 291 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 292 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 293 MALAYSIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 294 MALAYSIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 295 MALAYSIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 296 MALAYSIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 297 MALAYSIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 298 MALAYSIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 299 MALAYSIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 300 MALAYSIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 301 MALAYSIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 302 MALAYSIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 303 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 304 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 305 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 306 THAILAND TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 307 THAILAND TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 308 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 309 THAILAND SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 310 THAILAND TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 311 THAILAND PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 312 THAILAND MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 313 THAILAND CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 314 THAILAND EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 315 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 316 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 317 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 318 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 319 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 320 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 321 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 322 THAILAND CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 323 THAILAND CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 324 THAILAND ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 325 THAILAND GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 326 THAILAND PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 327 THAILAND ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 328 THAILAND NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 329 THAILAND ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 330 THAILAND OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 331 THAILAND OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 332 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 333 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 334 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 335 INDONESIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 336 INDONESIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 337 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 338 INDONESIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 339 INDONESIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 340 INDONESIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 341 INDONESIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 342 INDONESIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 343 INDONESIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 344 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 345 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 346 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 347 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 348 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 349 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 350 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 351 INDONESIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 352 INDONESIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 353 INDONESIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 354 INDONESIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 355 INDONESIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 356 INDONESIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 357 INDONESIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 358 INDONESIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 359 INDONESIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 360 INDONESIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 361 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 362 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 363 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 364 PHILIPPINES TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 365 PHILIPPINES TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 366 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 367 PHILIPPINES SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 368 PHILIPPINES TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 369 PHILIPPINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 370 PHILIPPINES MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 371 PHILIPPINES CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 372 PHILIPPINES EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 373 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 374 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 375 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 376 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 377 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 378 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 379 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 380 PHILIPPINES CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 381 PHILIPPINES CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 382 PHILIPPINES ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 383 PHILIPPINES GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 384 PHILIPPINES PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 385 PHILIPPINES ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 386 PHILIPPINES NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 387 PHILIPPINES ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 388 PHILIPPINES OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 389 PHILIPPINES OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 390 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

TABLE 391 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)

TABLE 392 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 393 VIETNAM TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)

TABLE 394 VIETNAM TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)

TABLE 395 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 396 VIETNAM SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 397 VIETNAM TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 398 VIETNAM PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 399 VIETNAM MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)

TABLE 400 VIETNAM CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 401 VIETNAM EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 402 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

TABLE 403 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)

TABLE 404 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)

TABLE 405 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)

TABLE 406 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)

TABLE 407 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)

TABLE 408 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 409 VIETNAM CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 410 VIETNAM CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 411 VIETNAM ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 412 VIETNAM GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 413 VIETNAM PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 414 VIETNAM ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 415 VIETNAM NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 416 VIETNAM ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 417 VIETNAM OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 418 VIETNAM OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

TABLE 419 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)

List of Figure

FIGURE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MARKET TYPE OF MANUFACTURER COVERAGE GRID

FIGURE 11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION

FIGURE 12 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING IS DRIVING THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 SMALL MOLECULE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET

FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050

FIGURE 16 HEALTHCARE EXPENDITURE PER CAPITA

FIGURE 17 SHARE OF API MARKET OCCUPIED IN ASIA

FIGURE 18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2021

FIGURE 19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2017-2028 (USD MILLION)

FIGURE 20 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, CAGR (2021-2028)

FIGURE 21 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, LIFELINE CURVE

FIGURE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2021

FIGURE 2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2017-2028 (USD MILLION)

FIGURE 3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 4 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 5 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, 2021

FIGURE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)

FIGURE 7 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, CAGR (2021-2028)

FIGURE 8 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, LIFELINE CURVE

FIGURE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2021

FIGURE 10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2017-2028 (USD MILLION)

FIGURE 11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, CAGR (2021-2028)

FIGURE 12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, LIFELINE CURVE

FIGURE 13 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, 2021

FIGURE 14 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)

FIGURE 15 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, CAGR (2021-2028)

FIGURE 16 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, LIFELINE CURVE

FIGURE 17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, 2021

FIGURE 18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, 2017-2028 (USD MILLION)

FIGURE 19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, CAGR (2021-2028)

FIGURE 20 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, LIFELINE CURVE

FIGURE 21 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, 2021

FIGURE 22 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, 2017-2028 (USD MILLION)

FIGURE 23 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, CAGR (2021-2028)

FIGURE 24 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, LIFELINE CURVE

FIGURE 25 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2021

FIGURE 26 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2017-2028 (USD MILLION)

FIGURE 27 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, CAGR (2021-2028)

FIGURE 28 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, LIFELINE CURVE

FIGURE 29 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, 2021

FIGURE 30 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)

FIGURE 31 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, CAGR (2021-2028)

FIGURE 32 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE

FIGURE 33 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SNAPSHOT (2020)

FIGURE 34 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2020)

FIGURE 35 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 36 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 37 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE (2021-2028)

FIGURE 38 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY SHARE 2020 (%)

View Detailed Information Right Arrow

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

The Asia-Pacific active pharmaceutical ingredients (API) market is expected to grow at a CAGR of 7.5% during the forecast period of 2021 to 2028.
The future market of the Asia-Pacific active pharmaceutical ingredients (API) market is expected to reach USD 86,222.48 million by 2028.
The major players in the Asia-Pacific active pharmaceutical ingredients (API) market are Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline plc., Aarti Industries Limited, Recipharm AB, Jubilant Pharmova Limited, LUPIN, Aurobindo Pharma, AbbVie Inc., AstraZeneca, Alkem Labs, Albemarle Corporation, Saneca Pharmaceuticals, Unichem Laboratories, Neuland Laboratories Ltd., Divi's Laboratories Limited., HIKAL Ltd., etc.
The countries covered in the Asia-Pacific active pharmaceutical ingredients (API) market are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific.

تصفح الصفحات ذات الصلة

Banner